Rett syndrome is one of the rare genetic disorders and almost exclusively affects girls. In Germany, an estimated 5,000 people are affected, with about 50 new cases each year. A disturbing sign: After ...
Taysha’s TSHA-102 shows 100% response in Rett, with FDA Breakthrough status and strong trial design supporting BLA hopes. Read why TSHA stock is a buy.
Taysha Gene Therapies has regained full rights to TSHA-102, its program that is in clinical evaluation to treat the neurodevelopmental disease Rett syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback